乳房切除术后即刻植入物乳房重建:门诊手术可行吗
该回顾性研究比较了2020年3月中旬前后因COVID-19方案调整由23小时术后观察转为当日出院的即刻假体乳房重建患者,共238例(门诊组119例、观察组119例)。结果显示两组在48小时、30天和90天的总并发症、重大并发症、分类并发症及重建失败率均低且无统计学差异,门诊组非手术患者护理费用显著更低(1509美元 vs 4045美元,P<0.001)。作者认为门诊手术安全且更具成本效益。
要点
- 门诊组与观察组在48小时、30天、90天的总并发症、重大并发症及重建失败率均低且无统计学差异。
- 30天再入院/再手术率门诊组7.6% vs 观察组9.2%(P=0.640),无统计学差异。
- 90天时放疗史(P=0.002)和吸烟(P<0.001)是重大并发症的显著预测因素。
核心结论
- 即刻假体乳房重建术后并发症低,门诊手术安全,不增加并发症风险,且更具成本效益。
- 作者建议外科医生可考虑对这类患者进行门诊管理,以减少COVID-19暴露和资源消耗,同时维持优质外科护理。
研究设计与样本
- 回顾性研究,纳入2019年3月至2021年4月在一家学术医院连续接受即刻假体乳房重建的患者。
- 2020年3月中旬前患者术后收治观察,之后患者当日出院;比较48小时、30天和90天的术后并发症及医院费用。
- 共纳入238例患者(门诊组119例,观察组119例)。
主要发现
- 在所有时间点,总并发症、重大并发症、分类并发症(伤口愈合、血清肿、血肿、感染、植入物暴露)和重建失败率均低,组间无统计学差异。
- 30天再入院/再手术率门诊组7.6% vs 观察组9.2%(P=0.640),无统计学差异。
- 48小时内无患者或手术因素预测重大并发症或血肿,90天内无因素预测感染。
- 90天时放疗史(P=0.002)和吸烟(P<0.001)是重大并发症的显著预测因素。
- 非手术患者护理平均费用门诊组1509美元 vs 观察组4045美元(P<0.001),门诊组显著更低。
关键数值与推荐
- 30天再入院/再手术率:门诊组7.6% vs 观察组9.2%(P=0.640)。
- 90天重大并发症预测因素:放疗史P=0.002,吸烟P<0.001。
- 非手术患者护理平均费用:门诊组1509美元 vs 观察组4045美元(P<0.001)。
临床怎么用
- 作者建议外科医生可考虑对即刻假体乳房重建患者进行门诊管理,以减少COVID-19暴露和资源消耗,同时维持优质外科护理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease of 2019 (COVID-19) poses unique challenges for breast reconstruction. At the authors' institution, COVID-19 postoperative protocols mandated patients undergoing immediate prosthetic breast reconstruction transition from 23-hour postoperative observation to same-day discharge. The authors sought to compare complications and hospital costs between these groups. METHODS: A retrospective study of consecutive patients who underwent immediate prosthetic breast reconstruction from March of 2019 to April of 2021 at an academic hospital was performed. Before mid-March of 2020, patients were admitted postoperatively for observation; after mid-March of 2020, patients were discharged the same day. Postoperative complications at 48 hours, 30 days, and 90 days and hospital costs were compared. RESULTS: There were 238 patients included (119 outpatient and 119 observation). Across all time points, total complications, major complications, categorical complications (wound healing, seroma, hematoma, infection, implant exposure), and reconstructive failures were low and not statistically different between groups. There were no differences in 30-day hospital readmission/reoperation rates (7.6% outpatient versus 9.2% observation; P = 0.640). No patient or surgical factors predicted major complication or hematoma by 48 hours or infection by 90 days. At 90 days, radiation history ( P = 0.002) and smoking ( P < 0.001) were significant predictors of major complications. Average patient care costs outside of surgery-specific costs were significantly lower for outpatients ($1509 versus $4045; P < 0.001). CONCLUSIONS: Complications after immediate prosthetic breast reconstruction are low. Outpatient surgery is safe, harboring no increased risk of complications. Furthermore, outpatient care is more cost-effective. Therefore, surgeons should consider outpatient management of these patients to minimize COVID-19 exposure and reduce resource consumption, all while maintaining excellent surgical care. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Keane AM, Keane GC, Skolnick GB, et al. Immediate Postmastectomy Implant-Based Breast Reconstruction: An Outpatient Procedure? Plast Reconstr Surg. 2023. PMID: 36728530. doi:10.1097/PRS.0000000000010156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。